FLT3 and acute myeloid leukemia: To date, intense investigation into molecular underpinnings of hematologic disease has led to the identification of key recurrent mutations such as MYD88L265P in lymphoplasmacytic lymphoma (LPL), BRAFV600E in hairy cell leukemia (HCL), and FLT3 in acute myelogenous leukemia (AML) that can be successfully targeted with cognate agents—ibrutinib, vemurafenib, and midostaurin respectively; producing encouraging results [7,8,9].